150 related articles for article (PubMed ID: 37667600)
1. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W
Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated colitis secondary to treatment with nivolumab-ipilimumab in a patient with stage IV kidney cancer: what do we do when corticosteroids fail?
Sánchez Cánovas M; López Martín A; Montenegro Luis S; Sánchez Saura A
Rev Esp Enferm Dig; 2022 Sep; 114(9):554-555. PubMed ID: 35081726
[TBL] [Abstract][Full Text] [Related]
7. [INTERSTITIAL NEPHRITIS CAUSED BY IPILIMUMAB AND NIVOLUMAB COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A CASE REPORT].
Ishii M; Takezawa K; Imamura R; Fukuhara S; Fujita K; Uemura M; Kiuchi H; Nonomura N
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):109-112. PubMed ID: 35444079
[TBL] [Abstract][Full Text] [Related]
8. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT-].
Fukatani Y; Daizumoto K; Kadoriku F; Yamamoto H; Sasaki Y; Ozaki K; Ueno Y; Tuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kanayama H; Niki M; Uehara H
Hinyokika Kiyo; 2022 Apr; 68(4):107-111. PubMed ID: 35613898
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract][Full Text] [Related]
11. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
12. Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma.
Takahashi M; Takishita M; Yamazato Y; Kakinoki H; Udo K; Tobu S; Noguchi M
CEN Case Rep; 2023 May; 12(2):237-241. PubMed ID: 36402939
[TBL] [Abstract][Full Text] [Related]
13. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.
Uemura H; Shinohara N; Tomita Y; Nonomura N; Yamada T; Yoshida A; Komoto A
Jpn J Clin Oncol; 2023 Jul; 53(8):730-737. PubMed ID: 37151051
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab.
Remolina-Bonilla YA; Jimenez-Franco B; Lam ET; Bourlon MT
Oncology (Williston Park); 2020 May; 34(5):171-174. PubMed ID: 32644176
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N
Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538
[TBL] [Abstract][Full Text] [Related]
16. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
17. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
[TBL] [Abstract][Full Text] [Related]
20. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
